Modality
mRNA
MOA
TROP-2 ADC
Target
PARP
Pathway
Cell Cycle
MyelofibrosisTTR Amyloidosis
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
May 2020
→ Jul 2029
Phase 1Current
NCT03563605
1,051 pts·TTR Amyloidosis
2024-10→2029-07·Active
NCT05588361
498 pts·Myelofibrosis
2020-05→TBD·Recruiting
1,549 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-07-223.3y awayPh2 Data· TTR Amyloidosis
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1/2
Recruit…
P1/2
Active
Catalysts
Ph2 Data
2029-07-22 · 3.3y away
TTR Amyloidosis
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03563605 | Phase 1/2 | TTR Amyloidosis | Active | 1051 | DAS28 |
| NCT05588361 | Phase 1/2 | Myelofibrosis | Recruiting | 498 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| CRS-337 | CRISPR Therapeutics | Phase 2/3 | PARP | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 |